# Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/efficacy-and-safety-of-sparsentan-versus-irbesartan-in-patients-with-iga/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Brad H. Rovin,Brad H Rovin,Jonathan Barratt,Hiddo J.L. Heerspink,Charles E. Alpers,Stewart Bieler,Dong-Wan Chae,Ulysses Diva,Jürgen Floege,Loreto Gesualdo,Jula K. Inrig,Donald E. Kohan,Radko Komers,Laura Ann Kooienga,Richard Lafayette,Bart Maes,Robert Małecki,Alex Mercer,Irene L. Noronha,Se Won Oh,Chen Au Peh,Manuel Praga,Priscila Preciado,Jai Radhakrishnan,Michelle N. Rheault,William E. Rote,Sydney C W Tang,Vladimir Tesar,Howard Trachtman,Hernán Trimarchi,James A Tumlin,Muh Geot Wong,Vlado Perkovic,Isabella Abbasciano,Catarina Abrantes,Simone Accarino,Sharon G. Adler,Annika Adoberg,Rouzbeh Afsari,Syeda B. Ahmad,Jafar Ahmed,Wooin Ahn,Bamidele Ajayi,Dariusz Aksamit,Saif Al‐Chalabi,É. Alamartine,Bassam Alchi,Mohammad Ali,Roberta Aliotta,Salem Almaani,Catarina Almeida,Edgar Almeida,Francisco de la Prada Álvarez,Patrícia Marques‐Alves,Francesca Annese,Gerald Appel,Alberto Ortiz Arduan,Maria Arena,Marta Calvo Arevalo,Dariush Arfaania,Carlos Arias,Emma Calatayud Aristoy,Eglė Ašakienė,Sarah Ashley,Ali Assefi,Alba Atenza,Asta Auerbach,Hanna Augustyniak-Bartosik,M Avella,Jonathan Ayling-Smith,Isabelle Ayoub,Christine Ayvazyan,Rocco Baccaro,Asha Bailey,Bruce Baker,Saravanan Balamuthusamy,José Ballarín,Rui Barata,Jerko Barbić,Dunja Barisic,Jonathan Barratt,José C. Barreto,Clara Barrios,Mirco Belingheri,Anna Benesova,Ana Ávila Bernabéu,Wanja Bernhardt,Shamik Bhadra,Luigi Biancone,Anne Blanchard,Elena Boaglio,Davide Bolignano,Andrew S. Bomback,Gustavo Andres Useche Bonilla,M Bordoli,Bhadran Bose,Neil Boudville,Donald Brandon,Donald Brandon,Karen Brown |
| Citations | 282 |
| DOI | 10.1016/s0140-6736(23)02302-4 |
| Fields | Medicine |
| Open Access | true |
| OA Status | green |
| OA URL | https://figshare.com/articles/journal_contribution/Efficacy_and_safety_of_sparsentan_versus_irbesartan_in_patients_with_IgA_nephropathy_PROTECT_2-year_results_from_a_randomised_active-controlled_phase_3_trial/24558439 |
| OpenAlex ID | https://openalex.org/W4388304602 |
| PMID | 37931634 |
| Type | article |
| Year | 2023 |

## Paper authors

Showing 10 of 29.

- [Brad H. Rovin](https://scholariq.org/researchers/brad-h-rovin/)
- [Vlado Perkovic](https://scholariq.org/researchers/vlado-perkovic/)
- [Syeda B. Ahmad](https://scholariq.org/researchers/syeda-b-ahmad/)
- [Andrew S. Bomback](https://scholariq.org/researchers/andrew-s-bomback/)
- [Charles E. Alpers](https://scholariq.org/researchers/charles-e-alpers/)
- [Howard Trachtman](https://scholariq.org/researchers/howard-trachtman/)
- [Hiddo J.L. Heerspink](https://scholariq.org/researchers/hiddo-j-l-heerspink/)
- [Jonathan Barratt](https://scholariq.org/researchers/jonathan-barratt/)
- [Salem Almaani](https://scholariq.org/researchers/salem-almaani/)
- [Haresh Selvaskandan](https://scholariq.org/researchers/haresh-selvaskandan/)

## Paper journal

- [The Lancet](https://scholariq.org/journals/the-lancet/)

## Paper primary topic

- [Renal Diseases and Glomerulopathies](https://scholariq.org/topics/renal-diseases-and-glomerulopathies/)

## Paper topics

- [Renal Diseases and Glomerulopathies](https://scholariq.org/topics/renal-diseases-and-glomerulopathies/)
- [Chronic Kidney Disease and Diabetes](https://scholariq.org/topics/chronic-kidney-disease-and-diabetes/)
- [Renal and Vascular Pathologies](https://scholariq.org/topics/renal-and-vascular-pathologies/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.